Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greil

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Antimicrobial Agents|October 16, 2010
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patientsS Perkhofer, C Lass-Flörl, M Hell, et al.
Leukemia Research|October 10, 1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemiaW Hilbe, U Apfelbeck, M Fridrik, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
Leukemia|January 12, 2017
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa StudyH Ludwig, K Weisel, M T Petrucci, et al.
British Journal of Cancer|October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analysesT Brodowicz, I Lang, Z Kahan, et al.
Leukemia & Lymphoma|March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-CW Hilbe, T Kühr, U Apfelbeck, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
British Journal of Cancer|March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialG Pfeiler, H Stöger, P Dubsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Antimicrobial Agents|October 16, 2010
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patientsS Perkhofer, C Lass-Flörl, M Hell, et al.
Leukemia Research|October 10, 1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemiaW Hilbe, U Apfelbeck, M Fridrik, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
Leukemia|January 12, 2017
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa StudyH Ludwig, K Weisel, M T Petrucci, et al.
British Journal of Cancer|October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analysesT Brodowicz, I Lang, Z Kahan, et al.
Leukemia & Lymphoma|March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-CW Hilbe, T Kühr, U Apfelbeck, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
British Journal of Cancer|March 21, 2013
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialG Pfeiler, H Stöger, P Dubsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerP Dubsky, M Filipits, R Jakesz, et al.
Pageof 15